Minute Insight: FDA Clears Fujirebio’s IVD For Alzheimer’s Disease
Executive Summary
Fujirebio Diagnostics’ Lumipulse G beta-amyloid ratio test assesses beta-Amyloid pathology in patients with suspected Alzheimer’s disease or other causes of cognitive decline. Lab tests for Alzheimer’s are already available, but this the first in vitro diagnostic for the disease that the agency has authorized.
You may also be interested in...
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
Pear Bankruptcy Filing Highlights Difficult Challenges Facing Digital Therapeutics
Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.